Isofol Medical

Isofol is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol’s lead clinical candidate, Modufolin®, is predicted to improve the outlook for cancer patients undergoing chemotherapy treatment with a range of antimetabolites. Isofol’s ongoing clinical trials are focusing on colorectal cancer and osteosarcoma. Isofol collaborates closely with its strategic R&D partner Merck Millipore, the world’s leading manufacturer of reduced folates.

Full Story >

stor orange

Modufolin® development

Modufolin® is a folate-based bio-modulator designed to replace leucovorin/levoleucovorin as the preferred treatment to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-flluorouracil). It is currently being evaluated in three Phase I/II studies, two in colorectal cancer and one in osteosarcoma.
 
Although several modern chemo drugs have been introduced that dramatically improve the treatment of many cancer diseases, they show limited effect in treating solid tumors. 5-FU and leucovorin/levoleucovorin is still the core treatment used today for colorectal cancer and Modufolin® has the potential to enable 5-FU to work more effectively.

Read more about Modufolin

Stay informed

Click the link below to stay informed about our progress.

Clinical trials

To find out the latest news about our ongoing clinical phase II trial please go to:

Development pipeline

Click the link below to find out more about our development pipeline:

News & Press information

First patient successfully treated with Modufolin® as a rescue therapy with high dose methotrexate (HDMTX) treatment in Osteosarcoma.
4/14/2015: Isofol Medical AB today announced that the first patient treated with Modufolin®, as rescue therapy, after treatment with two cycles of HDMX successfully fulfilled the study objectives. The patient is participating in a Phase I/II open-label, multicenter clinical trial where each patient is evaluated during two treatment cycles with HDMTX and Modufolin®. This is a safety/efficacy study in 3-6 patients and is intended to identify the dose with most favorable safety that mitigates HDMTX induced toxicity.
Stockholm Corporate Finance Life Science Day 2015
3/4/2015: Isofol’s Chief Scientific Officer, Anders Vedin presented at the Stockholm Corporate Finance Life Science Day 2015 at Operaterrassen in Stockholm.
Isofol Medical AB, Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden
Phone: +46 (0) 707 64 65 00 E-mail: info@isofolmedical.com